… Board with Leaders in Inherited Retinal Disease and RNA Therapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … of leading experts in inherited retinal disease and RNA therapies,” said Daniel A. de Boer, Chief Executive …
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
… company dedicated to changing lives by developing RNA therapies for severe rare and common diseases. We focus … and Cambridge, Massachusetts, USA. Learn more about RNA therapy and our Axiomer technology . We are on a mission …
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … Board (SAB) with leaders in inherited retinal disease and RNA therapy. The SAB members are: James Shannon, MD, Chair of …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … Board (SAB) with leaders in inherited retinal disease and RNA therapy. In February, ProQR announced its participation …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … Phase 1b/2 trial results of the intravitreal sepofarsen RNA therapy in LCA10 (encore presentations) Full-field … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber …
